PlainRecalls
FDA Drug Low Class III Terminated

Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01

Reported: June 20, 2018 Initiated: June 7, 2018 #D-0877-2018

Product Description

Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01

Reason for Recall

Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.

Details

Units Affected
1,620 bottles
Distribution
Product was distributed throughout the United States
Location
Morgantown, WV

Frequently Asked Questions

What product was recalled?
Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01. Recalled by Mylan Pharmaceuticals Inc.. Units affected: 1,620 bottles.
Why was this product recalled?
Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 20, 2018. Severity: Low. Recall number: D-0877-2018.